MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved ...

Jornay PM (methylphenidate) is a prescription drug for treating attention deficit hyperactivity disorder (ADHD) in adults and some children. The drug comes as an oral capsule that’s taken once daily.

The US Food and Drug Administration (FDA) has approved Jornay PM (Ironshore Pharmaceuticals), a novel formulation of methylphenidate that is taken in the evening instead of first thing in the morning ...

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ ...

Jornay PM utilizes the proprietary Delexis drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer ...

Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations. Capsules are a common oral solid dosage form and are produced in a variety of shapes, ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel ...

Methylphenidate HCl 20mg, 40mg, 60mg, 80mg, 100mg; ext-rel caps. Not recommended in pediatric patients <6yrs due to a higher plasma exposure and a higher incidence of adverse reactions (eg, weight ...

Jornay PM (methylphenidate) is a brand-name extended-release oral capsule that’s prescribed for ADHD in adults and some children. The cost of the drug with and without insurance can depend on several ...

Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations. Capsules are a common oral solid dosage form and are produced in a variety of shapes, ...